How digital algorithms are changing drug development

Artificial intelligence is gradually becoming one of the key technologies in clinical trials because modern drug development can no longer rely only on traditional manual data analysis. A clinical trial is a complex system involving patients, research centers, physicians, pharmaceutical companies, regulators, laboratories, electronic documentation systems and independent safety committees. Every stage requires accuracy, reproducibility and quality control. Against this background, artificial intelligence is not viewed as a replacement for medical judgment, but as a tool capable of accelerating information processing, detecting hidden patterns and reducing part of the organizational burden.

One of the most important areas of artificial intelligence use is patient recruitment for clinical trials. In many studies, enrollment takes months or even years, especially in rare diseases, oncology, autoimmune disorders or complex molecular subtypes of disease. Algorithms can analyze electronic medical records, laboratory results, imaging findings, genetic data and treatment history to identify patients who may potentially meet inclusion criteria. This does not mean automatic enrollment in a study, but it helps physicians identify suitable groups more quickly and reduces the risk of missing a patient who could fit the protocol.

A second important area is trial design itself. A traditional clinical trial protocol contains strict criteria, endpoints, visit schedules, methods for safety assessment and efficacy evaluation. Errors at this stage can lead to slow recruitment, overly complicated logistics, high numbers of exclusions or insufficient statistical power. Artificial intelligence can analyze previous studies, population characteristics, event rates, likely causes of patient dropout and historical efficacy data. Based on such information, it becomes possible to assess the feasibility of a protocol more accurately and reduce the risk that a study will prove difficult to conduct in a real clinical environment.

A particularly notable use of artificial intelligence is data monitoring. In the classical model, regulators or sponsors receive structured results after certain stages have been completed, when data have already been collected, cleaned and prepared for analysis. More modern digital systems make it possible to monitor trial data more rapidly and identify important safety or efficacy signals earlier. This does not mean uncontrolled access to individual patient information. Properly designed systems work with protected, structured and appropriately aggregated data, while preserving ethical and regulatory safeguards.

This shift is important not only technologically, but also conceptually. A clinical trial is no longer seen as a process in which data are evaluated only after a long period of accumulation. When properly organized, digital systems can identify safety signals earlier, detect unusual patterns of adverse events, reveal protocol deviations, highlight data quality problems or show differences between research centers. This is especially important in studies involving severe diseases, where delays in data interpretation can have clinical significance. However, faster access to information must not lead to premature conclusions. Every signal requires medical review, statistical assessment and an understanding of clinical context.

Another major direction is documentation automation. Drug development is accompanied by a large volume of written materials: protocols, reports, informed consent forms, safety descriptions, regulatory dossiers, responses to questions and internal analytical documents. Modern artificial intelligence systems can help structure these materials, identify inconsistencies, accelerate draft preparation and check alignment of data across documents. In this role, AI does not replace scientific writing, regulatory responsibility or medical review. It works as an auxiliary tool that can reduce repetitive work and help specialists focus on interpretation, quality and decision-making.

Medical image analysis also plays an important role in clinical practice and research. In oncology, cardiology, neurology and pulmonology, imaging findings are often part of trial endpoints. Artificial intelligence can assist in measuring tumor size, assessing lesion dynamics and analyzing MRI, CT, PET-CT or ultrasound images. The advantage of algorithms lies in their ability to apply the same method consistently across a large number of images. This may reduce variability between specialists, but it does not eliminate the need for expert interpretation. A patient’s image is always connected with clinical context, medical history, laboratory data and the technical quality of the examination.

Another promising area is digital biomarkers. Wearable devices, mobile applications and remote monitoring systems can record heart rate, activity level, sleep, pulse variability, oxygen saturation, gait, tremor and other parameters. In clinical trials, this creates the possibility of assessing a patient’s condition not only during visits, but also in daily life. This is especially important for chronic diseases, because traditional visits provide only isolated snapshots of the patient’s state. Artificial intelligence can analyze continuous data and detect changes that may be difficult to notice during routine observation. Nevertheless, digital biomarkers must be validated: it must be proven that the measured parameter is truly associated with a clinically meaningful outcome.

The regulatory question remains central. Artificial intelligence in medicine cannot be implemented only because the technology appears modern. A model must be assessed according to its reliability, its specific context of use, the quality of the underlying data and possible risks for clinical or regulatory decisions. This is important because the same model may be acceptable for exploratory analysis, but insufficient for making a critical decision about a drug’s safety or efficacy. The level of required evidence must correspond to the level of influence the algorithm has on the trial.

The main risks are related to the quality of source data, algorithmic bias, insufficient transparency and difficulty reproducing results. If a model was trained on an incomplete or non-representative population, it may perform worse in patients of a different age, sex, ethnic background, comorbidity profile or treatment history. In clinical trials, this is especially dangerous because incorrect selection or interpretation of data can affect the evaluation of a drug’s efficacy. Therefore, artificial intelligence must be treated as a regulated tool, not as a neutral technical layer. It is necessary to understand in advance what data were used, how the model was validated, where its limitations lie and who is responsible for the final decision.

Preserving the role of the physician and investigator remains a key principle. An algorithm can help identify a patient, assess dropout risk, detect an anomaly in data or suggest a preliminary classification of an image. But it does not carry clinical responsibility, does not understand an individual patient’s goals and cannot replace ethical evaluation of benefit and risk. Artificial intelligence is effective when it is embedded in a clear medical process: with quality control, result verification, documentation of changes and the ability to explain why a particular output was used.

The future of clinical trials will probably not be complete automation, but a hybrid model. In this model, artificial intelligence handles large-scale data analysis, pattern detection, technical checks and acceleration of routine processes, while medical specialists retain interpretation, responsibility and decision-making. Such a model can make trials faster, more precise and closer to real clinical practice. But its success will depend not on the number of implemented algorithms, but on how rigorously they are validated, how transparently they are used and how well they protect the interests of patients.